Galapagos NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Galapagos NV Creates Service Division Fidelta
Galapagos NV (Galapagos) announced that the research site in Zagreb, Croatia, will form the basis of a newly created service division, called Fidelta. Next to BioFocus and Argenta, this is the third service division of Galapagos. In September 2010 Galapagos acquired GlaxoSmithKline’s research center in Zagreb, Croatia, accessing capabilities to resource research programs from molecule through to the clinic for internal R&D programs. In order to enhance efficient use of these facilities, Galapagos has re-focused the Zagreb organization from internal to external outsourcing. Fidelta is a new drug discovery service company, being launched in the year that Croatia joins the European Union. It has chemistry, pharmacology (both in vitro and in vivo), biomarker, toxicology and ADME/PK capabilities, with specific experience in inflammation, infectious, metabolic, and oncology diseases.
Latest Developments for Galapagos NV
Latest Key Developments in Biotechnology
- BioSpecifics Technologies Corp announces FDA approval of XIAFLEX for treatment of peyronie's disease
- Xencor Inc announces closing of initial public offering
- Genmab reaches milestone from Janssen and raises FY 2013 financial guidance
- Genmab says milestone from Lundbeck puts revenue at top end of FY 2013 outlook range
- Share this
- Digg this